瑞舒伐他汀联合曲美他嗪治疗冠心病的临床效果分析
潘银萍;张文彬
【期刊名称】《中国卫生标准管理》 【年(卷),期】2015(000)008
【摘要】Objective To explore the use of coronary heart disease in patients with trimetazidine rosuvastatin combined therapy.Methods 120 cases of coronary heart disease patients for the study,included in time from August 2012 to August 2014,according to the random number table,randomized, observation group,60 patients received combination therapy(trimetazidine rosuvastatin atorvastatin),a control group of 60 patients received trimetazidine combined probucol therapy,the clinical efficacy of two groups were compared.Results The clinical efficacy in patients was 93.3% in the control group was 81.7%,significantly higher than the observation group,P<0.05; lipid levels in patients with post-treatment observation group to improve the situation better than the control
group,the
difference
was
parity
statisticaly
significant,P<0.05.Conclusion The patients with coronary heart disease trimetazidine
rosuvastatin
combined
treatment
effect
is
significant,worthy of attention and promotion.%目的：探究对冠心病患者采用曲美他嗪+瑞舒伐他汀联合治疗的效果。方法以120例冠心病患者为研究对象，纳入时间为2012年8月～2014年8月，按照随机数字表法随机分组，观察组60例，给予联合药物治疗（曲美他嗪+瑞舒伐他汀），对照组60例，给
瑞舒伐他汀联合曲美他嗪治疗冠心病的临床效果分析
